C反应蛋白与亚临床动脉样硬化之间的关系:达拉斯心脏研究
Amit Khera1, James A de Lemos, Ronald M Peshock
1Donald W. Reynolds Cardiovascular Clinical Research Center, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. amit.khera@utsouthwestern.edu
Circulation
|December 29, 2005
概括
较高的C-反应蛋白 (CRP) 表示心血管事件的风险较高. 然而,CRP是动脉样硬化负担的不良预测因素,因为当调整为传统风险因素时,关联会减弱.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 流行病学 流行病学
背景情况:
- 升高的C-反应蛋白 (CRP) 与心血管事件风险增加有关.
- 人们对CRP水平和现有的动脉样硬化负担之间的关系不太了解.
研究的目的:
- 调查C反应性蛋白 (CRP) 水平与亚临床动脉样硬化之间的关联.
- 确定CRP是否是冠状动脉化 (CAC) 和大动脉斑块的独立预测因素.
主要方法:
- 分析了达拉斯心脏研究,这是一个多民族,基于人口的样本,包括3373名30-65岁的成年人.
- 使用电子束CT扫描测量冠状动脉化 (CAC).
- 使用MRI评估了大动脉斑块.
主要成果:
- 患有CAC和大动脉斑块的受试者中位数CRP水平较高.
- 在男性中观察到一个温和的CRP增加趋势与更高的CAC.
- 在对传统心血管风险因素进行调整后,CRP和动脉样硬化指标之间的关联并不显著.
结论:
- 较高的CRP水平与亚临床动脉样硬化患病率的适度增加有关.
- 这种关联与传统的心血管风险因素并不独立.
- C-反应蛋白 (CRP) 是动脉样硬化负担的不良预测因素.
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

